Time-action Studies and Clinical Trial of Actrapid and Crystal II Novo Insulins

Clarke, B. F.; Munro, J. F.; Duncan, L. J. P.
July 1965
British Medical Journal;7/31/1965, Vol. 2 Issue 5456, p265
Academic Journal
No abstract available.


Related Articles

  • Rapid and Long-Acting Analogues as an Approach to Improve Insulin Therapy: An Evidence-Based Medicine Assessment. Heise, Tim; Heineman, Lutz // Current Pharmaceutical Design;Sep2001, Vol. 7 Issue 14, p1303 

    This review summarizes the results of clinical trials with the currently available insulin analogues (i.e., insulin lispro, insulin aspart, and insulin glargine) and evaluates their clinical benefit applying the standards of evidence-based medicine. All analogues show a more physiological...

  • Novo Nordisk in $42 MM Insulin Deal.  // Chemical Market Reporter;12/13/99, Vol. 256 Issue 24, p21 

    Reports that Novo Nordisk and Flamel Technologies entered into a development and licensing agreement for Flamel's Basulin basal insulin product for type I and II diabetes. Terms of the agreement; Amount in potential payments and royalties that Novo Nordisk will pay; Company to fund clinical...

  • Insulin Glargine. Gillies, P.S.; Figgitt, D.P.; Lamb, H.M. // Drugs;Feb2000, Vol. 59 Issue 2, p253 

    â–´ Insulin glargine is an extended-action biosynthetic human insulin. It precipitates in the neutral environment of subcutaneous tissue and is thus gradually absorbed into the bloodstream. The addition of small amounts of zinc to the formulation further delays absorption. â–´ In small...

  • Detection of Actrapid® by insulin assays. Morovat, Alireza // Annals of Clinical Biochemistry;May2007, Vol. 44 Issue 3, p315 

    A letter to the editor is presented in response to the article "Detection of Actrapid® by insulin assays.

  • Insulin Detemir and Its Unique Mechanism of Action. Chaykin, Louis B. // Internet Journal of Endocrinology;2007, Vol. 4 Issue 1, p1 

    Tight glycemic control with minimal risk for hypoglycemia is the goal of insulin therapy. Such control is difficult to accomplish with older insulin formulations, such as regular human insulin and neutral protamine Hagedorn (NPH) insulin because their pharmacokinetic/pharmacodynamic profiles...

  • Human Actrapid.  // Royal Society of Medicine: Medicines;2002, p286 

    The article presents information on Human Actrapid, a proprietary, prescription-only preparation of synthesized neutral soluble insulin. It is used in diabetic treatment to treat and maintain diabetic patients. It is available in vials for injection, in cartridges for use with NovoPen injectors...

  • Pork Actrapid.  // Royal Society of Medicine: Medicines;2002, p446 

    The article presents information on pork actrapid, a proprietary, prescription-only preparation of highly purified porcine soluble insulin, manufactured by Novo Nordisk AS. This drug is used in diabetic treatment to treat and maintain diabetic patients, and has a relatively short duration of...

  • Narrative Review: A Rational Approach to Starting Insulin Therapy. Mooradian, Arshag D.; Bernbaum, Maria; Albert, Stewart G. // Annals of Internal Medicine;7/18/2006, Vol. 145 Issue 2, p125 

    Background: The emergence of multiple insulin products has provided new opportunities to achieve diabetes control. However, the number of options has raised concerns about the optimal choices of products. Purpose: To briefly review the pharmacologic characteristics of currently available...

  • NOVO NORDISK A/S.  // MondayMorning;3/25/2013, Vol. 21 Issue 11, p1 

    The article offers information on the successful completion of the early-stage study of an oral-insulin NN1954 developed by the global healthcare company Novo Nordisk A/S. It mentions that Novo has completed the first of three phases of human testing by using Gastrointestinal Permeation...

  • A Critical Appraisal of the Role of Insulin Analogues in the Management of Diabetes Mellitus. Oiknine, Ralph; Bernbaum, Marla; Mooradian, Arshag D. // Drugs;2005, Vol. 65 Issue 3, p325 

    Insulin is one of the oldest and best studied treatments for diabetes mellitus. Despite many improvements in the management of diabetes, the nonphysiological time-action profiles of conventional insulins remain a significant obstacle. However, the advent of recombinant DNA technology made it...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics